Executive Reshuffles: LLY, S and RY Companies in Focus
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Pfizer's "weight gain drug" has achieved positive experimental results and is expected to fill the current situation of "no available drugs" in the fatal disease course.
① Unlike weight loss drugs, pfizer monoclinal antibody drug ponegromab aims to reduce factors that suppress appetite in the brain; ② In the field of cancer, about 80% of patients are diagnosed with cachexia and are expected to die within a year. ③ So far, the FDA has not approved any drugs for the treatment of cachexia.
Merck Keytruda With Eisai's Lenvima Succeeds in Late-stage Trial for Liver Cancer
Trending Stocks This Week as Market Bounces Back From Selloff
Merck Keytruda Cuts Mortality Risk in Gastric Cancer by 20%